Govorestat Phase 3 Data Propels APLT Stock 34% Surge
By ATTN Desk · Editorial oversight: Sean Han
Introduction
APPLIED THERAPEUTICS INC (NASDAQ: APLT) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in New York, New York. The company focuses on developing treatments for rare diseases with high unmet medical need, applying advances in biomarker science and molecular targeting. Its primary pipeline includes aldose reductase inhibitors (ARIs) and novel small molecules aimed at addressing genetic metabolic disorders and diabetic complications.
Corporate structure
Applied Therapeutics operates with a team of approximately 11–50 employees. Key leadership roles include corporate development, supply-chain operations, and chemistry, manufacturing, and formulation. Notable executives listed on LinkedIn include Constantine Chinoporos (Corporate Development), Kimberly Gutek Cox (Operations), and Andrew Wasmuth (Vice President, Chemistry, Manufacturing and Formulation). The company is publicly listed on Nasdaq under the ticker APLT.
Biopharmaceuticals by little plant
Recent developments and news
- September 5–7, 2025: Participation in the CMTA Patient & Research Summit in Indianapolis to engage with Charcot-Marie-Tooth (CMT) patients and researchers.
- September 2025: Attendance at the ASHG Annual Meeting in Boston, featuring discussions on PMM2-CDG, a congenital disorder of glycosylation.
- September 2025: Participation in CMT Awareness Month events, including the Denver and Boston CMT Walks, highlighting the company’s advocacy in peripheral neuropathy.
- September 2025: Presentation of scientific updates at the Neuromuscular Study Group Annual Meeting focused on therapies for peripheral neuropathies such as CMT.
- November 9, 2025: Filing of a Form 8-K to disclose material corporate developments (items 2.02, 5.02, 9.01).
- November 13, 2025: Submission of Form 10-Q covering the quarter ended September 30, 2025.
- November 14, 2025: Amendment No. 3 to Schedule 13G/A filed by T. Rowe Price Investment Management, Inc., reporting ownership of 21,403,300 shares (14.9% of common stock).
Financial and strategic analysis
As of November 17, 2025, APLT shares traded at USD 0.2929, reflecting a 34.17% increase on the day, with a trading volume of 27,388,812 shares. The company’s market capitalization is approximately USD 31.5 million. Applied Therapeutics does not pay a dividend and shows no insider or hiring momentum scores, as indicated by Yahoo Finance metrics.
A key component of the company’s strategy is its ARI franchise, led by the investigational compound govorestat (AT-007). Key pipeline milestones include:
| Compound | Indication | Development Stage |
|---|---|---|
| govorestat | Galactosemia | Phase 3 – 12-month interim data available |
| govorestat | Sorbitol Dehydrogenase (SORD Def.) | Phase 2 ready; Expanded Access open |
| govorestat | PMM2-CDG | Phase 2 ready; Expanded Access open |
| AT-001 | Diabetic cardiomyopathy | Phase 3 |
| AT-001 | Diabetic peripheral neuropathy | Phase 3 |
| AT-003 | Diabetic retinopathy | Phase 1 ready |
Applied Therapeutics holds an exclusive license with Mercury Pharma Group Limited to commercialize products containing AT-007. The company’s development strategy aims to leverage FDA biomarker guidance and established clinical endpoints to expedite the path from clinical development to approval.
Market position and industry context
Applied Therapeutics operates within the specialized sectors of rare diseases and diabetic complications in the biotech industry. Competitive pressures arise from both established pharmaceutical firms and emerging biotech companies. The company’s market capitalization and high share-price volatility (beta ≈ 2.33) reflect its profile as an early-stage enterprise. Institutional support from T. Rowe Price, which holds a 14.9% ownership stake, may indicate confidence in the company’s approach to drug development. The absence of product revenues and reliance on research and development pipelines position APLT as a candidate with considerable uncertainty and potential within the small-cap biotech sector.
tl;dr
APLT shares rose 34.17% to USD 0.2929 on November 17, 2025, following updates in its ARI pipeline. Interim data for govorestat's Phase 3 trial in galactosemia is available, with PMM2-CDG and SORD deficiency Phase 2 programs ready and Expanded Access open. The company filed a 10-Q on November 13 and an amended Schedule 13G/A on November 14, confirming T. Rowe Price’s 14.9% stake. An anticipated New Drug Application (NDA) submission for govorestat is expected in late 2025, with FDA acceptance possible in early 2026.